The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms

Sci Rep. 2017 Jul 14;7(1):5480. doi: 10.1038/s41598-017-05726-x.


We previously reported the CINSARC signature as a prognostic marker for metastatic events in soft tissue sarcomas, breast carcinomas and lymphomas through genomic instability, acting as a major factor for tumor aggressiveness. In this study, we used a published resource to investigate CINSARC enrichment in poor outcome-associated genes at pan-cancer level and in 39 cancer types. CINSARC outperformed more than 15,000 defined signatures (including cancer-related), being enriched in top-ranked poor outcome-associated genes of 21 cancer types, widest coverage reached among all tested signatures. Independently, this signature demonstrated significant survival differences between risk-groups in 33 published studies, representing 17 tumor types. As a consequence, we propose the CINSARC prognostication as a general marker for tumor aggressiveness to optimize the clinical managements of patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Gene Expression Profiling*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Neoplasms / genetics*
  • Prognosis
  • Survival Analysis
  • Treatment Outcome


  • Biomarkers, Tumor